This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_OESOPHAGUS_EXALLC for full statistics.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions
not C3_OESOPHAGUS
428575
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D00.1&
Hospital discharge: ICD-9
2301A
Cause of death: ICD-10
D00.1&
Cause of death: ICD-9
2301A
Cancer registry: Topography ICD-O-3
C15
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
2
3 out of 7 registries used, show all original rules.
20
Check minimum number of events None
20
Include endpoints None
20
Remove individuals based on genotype QC
20
CD2_INSITU_OESOPHAGUS
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Parent code in ICD-10
D00
Name in latin
Carcinoma in situ coli
Not enough data for upset plot.
Or the full data table
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of oesophagus
based on the number of shared cases.
Broader endpoints:
- Carcinoma in situ of oesophagus (controls excluding all cancers)
- Carcinoma in situ of oral cavity, oesophagus and stomach (controls excluding all cancers)
- Carcinoma in situ of oral cavity, oesophagus and stomach
- In situ neoplasms (controls excluding all cancers)
- In situ neoplasms
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 20 | - | 17 |
| Unadjusted prevalence (%) | 0.00 | - | 0.01 |
| Mean age at first event (years) | 66.38 | - | 66.53 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_OESOPHAGUS – Carcinoma in situ of oesophagus
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Carcinoma in situ of oesophagus
↥Endpoint not on priority list, no data to show.